[{"orgOrder":0,"company":"ATB Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ATB Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ATB Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"ATB Therapeutics \/ EQT Life Sciences"}]

Find Clinical Drug Pipeline Developments & Deals by ATB Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          STLE Annual Meeting
                          Not Confirmed
                          STLE Annual Meeting
                          Not Confirmed

                          Details : The proceeds will fund development of oncology and immunology therapeutics derived from innovative antibody payload platform, including novel antibody therapies for oncology and auto-immune disease.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 18, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : EQT Life Sciences

                          Deal Size : $56.0 million

                          Deal Type : Series A Financing

                          blank